FDA Commissioner Andrew von Eschenbach has named two people, one of whom should be very familiar to FDA observers, to top positions in the agency. Janet Woodcock, MDÂ will assume a newly created position, Chief Medical Officer, which will oversee scientific and planning operations. Woodcock has previously been Deputy Commissioner for Operations and director of the agency's drugs and biologics centers. John Dyer, MPH, has been named Deputy Commissioner for Operations and Chief Operating Officer. He will focus on issues concerning management, business processes, and information technology. He was previously COO at CMS, where he helped implement the vast reforms at that agency. In other words, Woodcock's charge will be to ensure the agency fulfills its scientific mission. Dyer's will be to ensure it fulfills it with as few bumps in the road as possible. Success in both is badly needed in this era of tribulation for the agency.
MD+DI Online is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.